EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient

Rosa María García-Álvarez, Maruxa Zapata-Cachafeiro, Irene Visos-Varela, Almudena Rodríguez-Fernández, Samuel Pintos-Rodríguez, Maria Piñeiro-Lamas, Teresa M Herdeiro, Adolfo Figueiras, Angel Salgado-Barreira, COVID-Drug Group

Inflammopharmacology · 2024

DOI: 10.1007/s10787-024-01475-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Rosa María García-Álvarez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service of Preventive Medicine and Public Health, Clinic Hospital of Santiago de Compostela, Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: COVID-19, Angiotensin-Converting Enzyme Inhibitors, Hospitalization, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Universidade de Santiago de Compostela.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the impact of prior chronic treatment with angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin-receptor blockers (ARBs), both as a group and by active ingredient, on severity (risk of hospitalization and mortality), progression of and susceptibility to COVID-19.

Methods

We conducted a multiple population-based case–control study in Galicia (north-west Spain). The study data were sourced from medical, administrative and clinical databases. We assessed: (1) risk of hospitalization, by selecting all patients hospitalized due to COVID-19 with PCR + as cases, and a random sample of subjects without a PCR + as controls; (2) COVID-19 mortality risk; (3) risk of disease progression; and (4) susceptibility to SARS-CoV-2, considering all patients with PCR + as cases, and the same subjects used in the previous model as controls. Adjusted odds ratios (aORs) were calculated.

Results

ACEIs and ARBs were shown to decrease the risk of hospitalization (aOR = 0.78 [95%CI 0.69–0.89] and aOR = 0.80 [95%CI 0.72–0.90] respectively), risk of mortality (aOR = 0.71 [95%CI 0.52–0.98] and aOR = 0.69 [95%CI 0.52–0.91] respectively), and susceptibility to the virus (aOR = 0.88 [95%CI 0.82–0.94] and aOR = 0.92 [95%CI 0.86–0.97] respectively). By active ingredient: use of enalapril was associated with a significantly lower risk of hospitalization (aOR = 0.72 [95%CI 0.61–0.85]), mortality (aOR = 0.59 [95%CI 0.38–0.92]) and susceptibility to COVID-19 (aOR = 0.86 [95%CI 0.79–0.94]); and use of candesartan was associated with a decreased risk of hospitalization (aOR = 0.76 [95%CI 0.60–0.95]), mortality (aOR = 0.36 [95%CI 0.17–0.75]) and disease progression (aOR = 0.73 [95%CI 0.56–0.95]).

Conclusion

This large-scale real-world data study suggest that enalapril and candesartan are associated with a considerable reduction in risk of severe COVID19 outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Angiotensin-Converting Enzyme InhibitorsHospitalizationAngiotensin Receptor AntagonistsAntihypertensive AgentsHumansMaleFemaleMiddle AgedAgedCase-Control StudiesSpainHypertensionAged, 80 and overDisease Progression

Stichwörter der Autor:innen

COVID-19CandesartanEnalaprilHospitalizationMortality

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive Agents

Autor:innen und Institutionen

  • Service of Preventive Medicine and Public Health, Clinic Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
  • Department of Preventive Medicine and Public Health, University of Santiago de Compostela, 15786, Santiago de Compostela, Coruña, Spain.
  • Department of Preventive Medicine and Public Health, University of Santiago de Compostela, 15786, Santiago de Compostela, Coruña, Spain. maruxa.zapata@usc.es.
  • Institute of Health Research of Santiago de Compostela, Santiago de Compostela, Spain. maruxa.zapata@usc.es.
  • Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), University of Santiago de Compostela, Santiago de Compostela, Spain. maruxa.zapata@usc.es.
  • Institute of Health Research of Santiago de Compostela, Santiago de Compostela, Spain.

Förderung

  • Instituto de Salud Carlos III
  • Universidade de Santiago de Compostela

Zitieren

APA

García-Álvarez, R. M., Zapata-Cachafeiro, M., Visos-Varela, I., Rodríguez-Fernández, A., Pintos-Rodríguez, S., Piñeiro-Lamas, M., Herdeiro, T. M., Figueiras, A., Salgado-Barreira, A., & COVID-Drug Group (2024). Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01475-2

Vancouver

García-Álvarez RM, Zapata-Cachafeiro M, Visos-Varela I, Rodríguez-Fernández A, Pintos-Rodríguez S, Piñeiro-Lamas M, et al. Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01475-2

BibTeX
@article{Garcalvarez2024,
  author = {García-Álvarez, Rosa María and Zapata-Cachafeiro, Maruxa and Visos-Varela, Irene and Rodríguez-Fernández, Almudena and Pintos-Rodríguez, Samuel and Piñeiro-Lamas, Maria and Herdeiro, Teresa M and Figueiras, Adolfo and Salgado-Barreira, Angel and COVID-Drug Group, COVID-Drug Group},
  title = {Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient},
  journal = {Inflammopharmacology},
  year = {2024},
  doi = {10.1007/s10787-024-01475-2}
}
Kostenlos starten →